Page 4 - Efficacy Data News Today

New Data Adds to Growing Body of Clinical Evidence in Support of APVO436 Clinical Potential SEATTLE, WA - July 18, 2023 - Aptevo Therapeutics Inc. , a clinical-stage...

ADI-001 demonstrated 71% overall response rate (ORR) and 63% complete response (CR) rate across all dose levels in patients with median 4 prior lines of therapy; 50% of patients enrolled had previously progressed on anti-CD19 chimeric antigen receptor T cell (CAR T) therapy 83% ORR and 67% CR rate observed in heavily pre-treated patients who had progressed on prior CAR T Six-month CR rate consistent with autologous CAR T cell therapy Favorable safety with no significant incidence of CRS (cytokin...

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Jun 26, 2023--

InMed Pharmaceuticals Inc (NASDAQ: INM) shares are trading lower after the company released safety and efficacy results from its Phase 2 clinical trial (755-201-EB) for symptoms related to Epidermolysis Bullosa (EB). The Phase 2 Trial enrolled 19 patients, with data from one patient excluded from efficacy analysis due to protocol deviation. Chronic itch improved in 12 patients (66.7%), with some patients showing the same level of improvement with INM-755cannabinol (CBN) cream as with the control

Drs Armstrong and Manning review the safety and efficacy data from the ALSYMPCA trial of radium-223 in patients with mCRPC.

/PRNewswire/ -- Synapse Biomedical, Inc. announced today that the FDA has granted premarket approval (PMA) of the NeuRx® Diaphragm Pacing System (NeuRx DPS®)...

Announced interim safety and efficacy data for ADI-001 in ongoing Phase 1 study for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL); Next data update expected in Q2 2023Announced preclinical data for differentiated chimeric antigen receptor (CAR) and chimeric adaptor (CAd) progr...

But then you ask, where is the efficacy data? is there any proof that in any demographic this is necessary, effective, and save? we know for young healthy adults, men especially, there is a one in 5,000 chance of myocarditis, or a serious adverse event. but where is the benefit to counteract that? if you have all risk and no benefit, literally doing? i think the government has been very opaque with the safety data. we know that the fdas own advisory committee members have complained about that. ...

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

TAK-003 Recommended for the Prevention of Dengue Disease Caused by Any Dengue Virus Serotype in Individuals Four Years of Age and Older in the EU and in Dengue-Endemic Countries Participating in